Bioplus Life Sciences Private Limited

Bioplus Life Sciences Private Limited, established on March 19, 2004, is a private limited company headquartered in Bangalore, Karnataka, India. The company is registered under the Corporate Identification Number (CIN) U24232KA2004PTC033578. Its authorized capital stands at ₹36.35 crore, with a paid-up capital of ₹3.00 crore. The registered address is S.No.10-1A, Hoodi Village, Krishnarajapuram Hobli, Bangalore, Karnataka, India.

Bioplus Life Sciences specializes in the manufacturing and marketing of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio encompasses nutritional supplements such as vitamins, folic acid, and glucosamine, catering to various therapeutic needs. As of March 31, 2022, Bioplus Life Sciences employed approximately 276 individuals, reflecting its commitment to quality and innovation in the pharmaceutical sector.

Bioplus Life Sciences operates manufacturing facilities in Bangalore, Karnataka, India. These facilities are equipped to produce a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company emphasizes quality control and adheres to stringent manufacturing practices to ensure the safety and efficacy of its products. While specific production capacities are not publicly disclosed, the facilities are designed to meet both domestic and international demand.

The leadership team at Bioplus Life Sciences Private Limited includes:

• Mr. Sundeep Aurora: Director, appointed on May 12, 2008.

• Mr. Sunjeev Aurora: Director, appointed on May 12, 2008.

• Ms. Neha Aurora: Additional Director, appointed on April 1, 2025.

The leadership team is responsible for steering the company's strategic direction and ensuring operational excellence in the pharmaceutical manufacturing sector.

Bioplus Life Sciences Private Limited has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to market its pharmaceutical formulations in these regions. This includes compliance with Good Manufacturing Practices (GMP) and other regulatory standards set by authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and Therapeutic Goods Administration (TGA). These approvals underscore Bioplus's commitment to maintaining high-quality standards and meeting the stringent requirements of international markets.

Bioplus Life Sciences Private Limited has strategically focused on penetrating emerging markets in Africa, Latin America, and Southeast Asia. The company has pursued World Health Organization (WHO) prequalification for its products, facilitating access to these regions. By obtaining WHO prequalification, Bioplus ensures that its pharmaceutical formulations meet international quality standards, thereby enhancing their acceptance and distribution in these emerging markets. This strategic approach enables the company to address the growing healthcare needs in these regions effectively.

Bioplus Life Sciences Private Limited demonstrates a diversified geographic strategy by expanding its footprint across both regulated and emerging markets. This approach mitigates concentration risk and leverages growth opportunities in various regions. The company's strategic direction focuses on balancing its presence in established markets with emerging ones, ensuring a resilient and adaptable business model. By aligning its operations with global healthcare demands, Bioplus aims to achieve sustainable growth and long-term success.

Bioplus Life Sciences Private Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical formulations to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, seeking approval for marketing in the U.S. market. Additionally, Bioplus has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality control measures of its products. The company maintains a history of successful FDA inspections, reflecting its adherence to stringent regulatory standards and commitment to product quality.

Bioplus Life Sciences Private Limited has obtained World Health Organization (WHO) prequalification for its pharmaceutical formulations, affirming that its products meet international quality standards. The company has also secured European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating compliance with the EU's stringent manufacturing and quality control requirements. These certifications enhance the company's credibility and facilitate the distribution of its products in global markets, including Europe and other regions recognizing WHO prequalification.

Bioplus Life Sciences Private Limited holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers for its manufacturing facilities, ensuring compliance with regional regulations. Bioplus has also secured export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), authorizing the export of its pharmaceutical formulations to various international markets. These regulatory approvals underscore the company's commitment to maintaining high-quality standards and adhering to both national and international regulatory requirements.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Bioplus Life Sciences Private Limited by regulatory authorities such as the FDA. This absence of adverse regulatory actions suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by health authorities.

Bioplus Life Sciences Private Limited operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. Key competitors include established pharmaceutical manufacturers with a diverse product portfolio and a global presence. While specific market share data is not publicly disclosed, Bioplus's focus on high-quality pharmaceutical formulations and adherence to international regulatory standards position it as a competitive player in the industry. The company's strategic emphasis on both regulated and emerging markets further enhances its competitive edge.

Bioplus Life Sciences Private Limited distinguishes itself through its commitment to quality, innovation, and regulatory compliance. The company's diverse product portfolio, including nutritional supplements and pharmaceutical formulations, caters to a wide range of therapeutic needs. Its strategic focus on obtaining international certifications, such as WHO prequalification and EU GMP, enhances its credibility and facilitates access to global markets. Additionally, Bioplus's emphasis on research and development enables it to introduce innovative products that meet evolving healthcare demands.

Bioplus Life Sciences Private Limited's current strategic direction centers on expanding its presence in both regulated and emerging markets. The company's focus on obtaining international certifications and regulatory approvals underscores its commitment to maintaining high-quality standards and meeting global healthcare needs. Looking ahead, Bioplus aims to leverage its strengths in manufacturing and marketing pharmaceutical formulations to achieve sustainable growth and enhance its position in the global pharmaceutical industry.

Bioplus Life Sciences Private Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations. The company's export volume and consistency reflect its reliability as a supplier. Indicators of reliability include adherence to international quality standards, successful regulatory approvals, and a history of compliance with regulatory authorities. These factors collectively position Bioplus as a dependable partner in the pharmaceutical supply chain.

Importers should verify the following certifications when considering Bioplus Life Sciences Private Limited as a supplier:

• FDA Facility Registration: Confirm the registration status of Bioplus's manufacturing facilities with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure that Bioplus's products are prequalified by the World Health Organization, indicating compliance with international manufacturing standards.

• EU GMP Certificate: Verify that Bioplus holds a valid European Union Good Manufacturing Practice certificate, demonstrating adherence to EU manufacturing and quality control requirements.

• ISO Certification: Check for relevant International Organization for Standardization certifications that attest to the company's quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Bioplus Life Sciences.

When conducting due diligence on Bioplus Life Sciences Private Limited, consider the following steps:

• Verify Regulatory Approvals: Confirm that Bioplus holds the necessary certifications and approvals from relevant regulatory authorities, including the FDA, WHO, EU, and CDSCO.

• Assess Financial Health: Review the company's financial statements to evaluate its financial stability and growth trajectory.